MK-677 (Ibutamoren)

Most Common Uses

MK-677 is a non-peptide growth hormone secretagogue primarily used in clinical research and off-label settings to stimulate growth hormone and insulin-like growth factor 1 (IGF-1) release. It is frequently studied for treating growth hormone deficiency, particularly in children and adults with impaired hormone production, to support growth and metabolic health. MK-677 (Ibutamoren) is also explored for its potential to counteract muscle wasting in conditions like cachexia or sarcopenia, helping preserve lean muscle mass and strength. In aging populations, it is investigated for improving bone density and reducing frailty, aiming to enhance physical function.

Its use in bodybuilding and athletic communities is common due to its ability to promote muscle growth and recovery. Despite its short half-life, MK-677 has prolonged effects on IGF-1 levels make it a valuable tool in research and performance enhancement, though careful monitoring is needed due to side effects like increased appetite.

Mechanism of Action

MK-677 functions as a non-peptide growth hormone secretagogue by mimicking the action of ghrelin, a hormone that stimulates appetite and growth hormone release. It binds to ghrelin receptors (GHSR1a) in the pituitary gland and hypothalamus, triggering a cascade that increases the secretion of growth hormone and IGF-1. This process enhances protein synthesis, muscle growth, and bone mineralization, while also influencing metabolism and energy balance.

Unlike direct growth hormone administration, MK-677 amplifies the body’s natural pulsatile growth hormone release, preserving physiological feedback mechanisms. Its oral bioavailability and half-life allow sustained elevation of IGF-1 levels, supporting its use in conditions like growth hormone deficiency or muscle wasting. Additionally, MK-677 activation of ghrelin receptors stimulates appetite, which can benefit patients with cachexia but requires monitoring to manage potential weight gain.

Structure and Pharmacology

MK-677 has a chemical structure defined by the molecular formula C27H36N4O5S. Structurally, it is a spiroindoline derivative designed to mimic the action of ghrelin, featuring a complex arrangement of carbon, nitrogen, oxygen, and sulfur atoms that enable high-affinity binding to ghrelin receptors. Its molecular weight of approximately 528.7 g/mol supports its stability and oral bioavailability. The design of MK-677 allows it to effectively stimulate growth hormone release while maintaining a favorable pharmacokinetic profile for therapeutic applications.

Pharmacologically, MK-677 is administered orally and works by binding to ghrelin receptors (GHSR1a) in the pituitary and hypothalamus to stimulate the release of growth hormone and IGF-1. This mechanism promotes protein synthesis, muscle growth, and bone density, making it valuable for conditions like growth hormone deficiency, muscle wasting, and age-related frailty. With a half-life of about 4–6 hours, MK-677 (Ibutamoren) sustains elevated IGF-1 levels for up to 24 hours, allowing once-daily dosing. It is metabolized primarily in the liver, with excretion through urine and feces. The compound’s ability to increase appetite via ghrelin receptor activation supports its use in cachexia but requires monitoring to manage potential side effects like water retention or mild hyperglycemia.

Dosages

MK-677 is typically administered orally in tablet or capsule form. For clinical research and therapeutic purposes, such as treating growth hormone deficiency or muscle wasting, daily doses commonly range from 10 to 25 milligrams, taken once daily, often at bedtime to align with natural growth hormone secretion patterns. In studies addressing age-related frailty or cachexia, similar dosing regimens are used, adjusted based on patient response and tolerance. Bodybuilding and athletic applications often involve doses at the higher end of this range, around 20 to 25 milligrams daily, to support muscle growth and recovery. Careful monitoring is necessary to manage potential side effects like increased appetite or water retention, ensuring safe use across its applications.

Warnings and Cautions

MK-677 (Ibutamoren) requires careful administration due to its effects on growth hormone and IGF-1 levels. Its stimulation of appetite through ghrelin receptor activation can lead to significant weight gain, particularly in individuals prone to overeating, necessitating dietary monitoring. Prolonged use may cause water retention, resulting in edema or increased blood pressure, which requires caution in patients with cardiovascular conditions. MK-677 can elevate blood glucose levels, posing risks for those with diabetes or insulin resistance, who need regular monitoring to prevent hyperglycemia.

Some users report mild side effects like fatigue, joint pain, or headaches, which may subside with dose adjustments. Its long-term effects remain understudied, so extended use should be approached cautiously, especially in healthy people using it for non-medical purposes like bodybuilding. With its half-life and sustained IGF-1 elevation, MK-677 demands careful dosing, typically 10–25 milligrams daily, to balance benefits with potential risks, particularly in elderly patients or those with liver or kidney impairments.

Research & Clinical Trials

Reverses Diet-Induced Catabolism

The study found that MK-677, an orally active growth hormone (GH) secretagogue, can effectively reverse diet-induced protein catabolism in healthy adults. During periods of caloric restriction, participants typically experienced nitrogen loss, indicating protein breakdown, but treatment with MK-677 improved nitrogen balance and prevented this loss compared with placebo. Ibutamoren significantly increased GH and IGF-I levels, as well as IGF-binding protein-3, demonstrating clear anabolic effects, while having no significant impact on cortisol or prolactin levels. The treatment was generally well tolerated and without serious side effects. These findings suggest that MK-677 may have potential as a therapeutic option for patients experiencing catabolic conditions due to acute or chronic illnesses, by promoting protein retention and supporting anabolic processes. [1]

Increases Muscle Mass and GH Levels in Older Adults

The study concluded that MK-677, an oral ghrelin mimetic, effectively increased growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels in older adults to the range seen in healthy young adults without serious adverse effects. Over 12 months, MK-677 (Ibutamoren) significantly increased fat-free mass (FFM), total appendicular skeletal muscle mass (TASM), and intracellular water, reflecting gains in muscle and cell mass. Body weight and limb fat also increased, but there were no significant changes in abdominal visceral fat.

While these anabolic effects improved body composition, they did not translate into measurable improvements in muscle strength or physical function. MK-677 (Ibutamoren) was generally well tolerated, with mild, transient side effects such as increased appetite, lower extremity edema, and muscle pain. These results suggest MK-677 (Ibutamoren) may help prevent age-related declines in muscle mass and GH secretion, though longer-term studies are needed to assess functional benefits and overall clinical impact. [2]

Clinical Potential and Limitations of Growth Hormone Secretagogues

The study concluded that growth hormone secretagogues (GHSs), including MK-677 (Ibutamoren) , are effective at stimulating the body’s own GH and IGF-1 production in adults and children, with potential benefits for increasing lean body mass, improving growth velocity in children, enhancing appetite, supporting recovery in catabolic or wasting states, improving bone turnover, and positively affecting sleep. MK-677 (Ibutamoren), in particular, has demonstrated good oral bioavailability, longer half-life, and tolerability over longer treatment periods, producing increases in fat-free mass and IGF-1 without serious adverse effects in most studies.

However, the evidence is limited by small study sizes, short durations, and few long-term trials, so functional outcomes like muscle strength, exercise performance, or meaningful improvements in recovery remain unclear. A consistent finding is an increased risk of hyperglycemia and reduced insulin sensitivity with GHS use. Overall, the literature supports potential clinical applications of GHSs in GH deficiency and wasting, but larger, long-term studies are needed to confirm safety, efficacy, and effects on functional outcomes, body composition in combination with exercise, and long-term health risks. [3]